Stephanie Diaz; Investor Relations Manager; Viking Therapeutics Inc. Brian Lian; President, Chief Executive Officer, Director; Viking Therapeutics Inc. Greg Zante; C ...
Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...
Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to scale down their dosing if, for example, they experienced side effects like ...
Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...
Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...
Viking held cash, cash equivalents and short-term investments of $903M, compared to $362M as of December 31, 2023. 2024 ...
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Investor's Business Daily on MSN10h
Viking Therapeutics Plummeted 10% On Its Earnings Report. Here's Why.Viking Therapeutics stock plunged late Wednesday on an earnings report that included mostly incremental updates for its ...
Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst ...
Novo Nordisk shares rose 4.5% after a strong Q4 profit beat, driven by high demand for obesity drug Wegovy, despite forecasting slower sales growth for 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback